Comparison of Polydrug Use Prevalences and Typologies between Men Who Have Sex with Men and General Population Men, in Madrid and Barcelona
Por:
Guerras, JM, Hoyos, J, de Olalla, PG, de la Fuente, L, Herrero, L, Palma, D, del Romero, J, Garcia-Perez, JN, Belza, MJ
Publicada:
1 nov 2021
Resumen:
This study compares the prevalence of drug use and the typologies of polydrug use (PDU) in men who have sex with men (MSM) and general population men (GPM). Participants were men aged 16-64, living in the provinces of Madrid and Barcelona: 1720 were recruited in a GPM survey, and 2658 were HIV-negative MSM from HIV/STIs diagnosis services. Lifetime and last-year prevalence of drug use and prevalence ratios (PRs) of MSM to GPM for the different drugs were calculated using Poisson regression. Latent class analysis (LCA) was performed to identify typologies of PDU. Lifetime use of the drugs considered was higher in MSM, and even higher for drug use in the last-year: PRs for cannabis, hallucinogens and cocaine ranged from 2-5; for amphetamine, ecstasy and methamphetamine 12-16; and above 60 for ketamine, GHB/GBL, inhalants and mephedrone. In the LCA for lifetime PDU four classes arose from the GPM (No-PDU (79.6%); Conventional PDU (13.8%); Intensive conventional PDU (4.9%); Heavy PDU (1.8%)) and four among MSM (No-PDU (57.7%); Conventional PDU plus poppers (18.8%); PDU preferring chemsex drugs (6.4%); Heavy PDU (17.2%)). For PDU during the last-year, three classes arose in the GPM: No-PDU (94.7%); Conventional PDU (4.3%); Heavy PDU (0.9%). For MSM, we identified four classes: No-PDU (64.7%); Conventional PDU plus poppers (15.6%); PDU preferring chemsex drugs (6.2%); Heavy PDU (13.5%). MSM should be considered a priority group for the prevention of the use of all drugs but the heterogeneity of PDU typologies regarding users' preference towards conventional and/or sexualised drugs needs to be taken into account.
Filiaciones:
Guerras, JM:
Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid 28029, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain
Hoyos, J:
Univ Complutense Madrid, Dept Salud Publ & Maternoinfantil, Madrid 28040, Spain
de Olalla, PG:
CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain
Agencia Salut Publ Barcelona, Serv Epidemiol, Barcelona 08023, Spain
de la Fuente, L:
Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid 28029, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain
Herrero, L:
Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid 28029, Spain
Palma, D:
CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain
Agencia Salut Publ Barcelona, Serv Epidemiol, Barcelona 08023, Spain
del Romero, J:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos, Ctr Sanitario Sandoval, Madrid 28010, Spain
Garcia-Perez, JN:
Hosp Valle De Hebron, Unidad ITS Vall dHebron Drassanes, Barcelona 08001, Spain
Belza, MJ:
CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain
Inst Salud Carlos III, Escuela Nacl Sanidad, Madrid 28029, Spain
gold, Green Published
|